Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Heron Therapeutics Inc (HRTX) vs Financial Select Sector SPDR Fund (XLF) Price & Performance

Heron Therapeutics IncTrade
Financial Select Sector SPDR FundTrade

Price performance (Past 24H)

Key statistics

Heron Therapeutics Inc vs Financial Select Sector SPDR Fund — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Financial Select Sector SPDR Fund trades at $57.85. The key difference: Financial Select Sector SPDR Fund is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

HRTXXLF
Market Cap
$63.41M
Sector
Health
52-Week High
$1.49$58.01
52-Week Low
$0.32$47.80
Enterprise Value
$161.31M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Heron Therapeutics Inc

Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.

HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.

Financial Select Sector SPDR Fund

XLF trades at $57.60, down 0.35% on the day, with a bullish technical signal driven by moving averages and strong momentum indicators. The ETF recently touched an all-time high, supported by robust inflows into financial sector ETFs and strong Q2 earnings from major banks. A dividend of $0.19 is scheduled for June 2026, adding income appeal.

Outlook remains positive given sector strength and institutional interest, though overbought RSI levels suggest near-term consolidation risks. Key opportunities include diversification benefits and yield; risks involve interest rate sensitivity and market volatility.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX

About Financial Select Sector SPDR Fund

The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.

Read more on XLF